کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2406902 | 1103101 | 2007 | 9 صفحه PDF | دانلود رایگان |

AimRotavirus is the leading cause of acute gastroenteritis in children. Two rotavirus vaccines (RotaTeq® and Rotarix®) have recently completed clinical trials. We investigated whether routine infant immunisation with either vaccine can be cost effective.MethodsWe compared costs and outcomes of vaccination using a cohort model, following children over the first 5 years of life. We estimated health provider costs, economic costs and quality adjusted life years (QALYs) lost due to rotavirus-related deaths, hospital admissions, nosocomial infections, accident and emergency attendances, general practioner consultations and calls to NHS Direct.ResultsUnder base case assumptions, a programme using RotaTeq® (priced at £25 a dose) would cost the health provider £79,900 per QALY gained. Using Rotarix® (priced at £35 a dose) would cost £61,000 per QALY gained. Univariate and multivariate sensitivity analysis indicate that at these prices an immunisation programme would be unlikely to be cost-effective for any realistic value of the key parameters.ConclusionsRotavirus immunisation could reduce the substantial short-term morbidity burden due to rotavirus, but is unlikely to be deemed cost effective unless the vaccine is competitively priced.
Journal: Vaccine - Volume 25, Issue 20, 16 May 2007, Pages 3971–3979